| Name | Title | Contact Details |
|---|
Birmingham Gastroenterology Associates is a medical practice that specializes in the treatment of diseases and disorders of the digestive tract, including the esophagus, stomach, intestines, liver and pancreas.
Aid and Assist at Home, Inc. is a Nashville, TN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
ReviveHealth is a healthcare subscription membership that offers unique healthcare programs for individuals, employers, and associations. They provide access to virtual primary, urgent & pediatric care, physical & mental health therapy, with Rxs inclu...
Simulation & Training Environment Laboratory is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Neuralstem is a dual platform regenerative medicine company. The company`s technology enables the production of regionally specific, physiologically relevant neural stem cells for therapeutic use for the treatment of central nervous system (CNS) diseases and has enabled the discovery of a library of patented small molecule neurogenic compounds to treat psychological and cognitive disorders. Neuralstem`s small molecule drug discovery program screens human neural stem cell lines for compounds that may stimulate neurogenesis in the brain, possibly reversing pathologies associated with certain CNS conditions. The company`s lead compound, NSI-189, has completed FDA Phase Ia and Ib safety trials for the treatment of major depressive disorder (MDD). Neuralstem is expecting to launch a Phase II study for MDD in 2015. Neuralstem`s first stem cell therapy product, NSI-566, a spinal cord-derived neural stem cell line, is in ongoing clinical trials to treat amyotrophic lateral sclerosis (ALS, or Lou Gehrig`s disease), for which it has received orphan status designation by the FDA. Dosing in a phase IIa trial was completed in July, 2014. The next trial is anticipated to commence in 2015. In addition to ALS, the company is conducting an NSI-566 Phase I trial in chronic spinal cord injury, with NSI-566 clinical development also underway to treat ischemic